Shabsigh, Ahmad http://orcid.org/0000-0003-1376-4977
Kleinmann, Nir
Smith, Angela B.
Scherr, Douglas
Seltzer, Elyse
Schoenberg, Mark
Lerner, Seth P.
Funding for this research was provided by:
UroGen Pharma
Article History
Received: 16 November 2020
Accepted: 5 February 2021
First Online: 7 March 2021
Compliance with ethical standards
:
: AS and NK have been investigators and consultants for UroGen Pharma. ABS has been a consultant for UroGen Pharma, Merck, and Photocure, and an investigator for PCORI. SPL has received grant support for clinical trials from UroGen Pharma, Endo, FKD, JBL (SWOG), Roche/Genentech (SWOG), Vaxiion, and Viventia; has been a consultant for UroGen Pharma, Ferring, GLG, Merck, Pfizer, Roche/Genentech, QED, and Verity; has received honoraria from UroToday and Grand Rounds in Urology; is a patent holder for TCGA classifier; and has received compensation in his role as co-editor in chief for Bladder Cancer and as co-editor for the bladder cancer section of UpToDate<sup>®</sup>. ES and MS are employees of UroGen Pharma. DS declares no competing interests.
: The study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice and the Declaration of Helsinki, and was approved by the designated ethics committees and institutional review boards at each site.
: All participants provided written informed consent.